Drs. Paul Kruithof

Paul Kruithof graduated as a pharmacist from the University of Groningen in 2022. During his university studies, he was part of several research programs involving drug discovery in diabetes type 2 and malaria. Afterwards, he came to the clinical Pharmacy and Toxicology department in the Maastricht University Medical Centre to start his PhD. His current research aims to study and improve safety and cost-effectiveness of anticancer treatments in lung oncology.

Supervisory Team

• Promotor: Dr. Lizza Hendriks

• Co-promotors: Dr. Sander Croes
                                Dr. Robin van Geel

   

Participations, projects and additional duties:

Projects

• Osiboost 2 clinical trial (Coordinating investigator) https://clinicaltrials.gov/study/NCT05748093  
• Safety of oral anticoagulants in patients with cancer (nWMO: DOAC-SMI 2)
• Epidemiology of immune-related adverse events in patients receiving immunotherapy
• Pharmacokinetic (PK) modelling of osimertinib to predict effectiveness of PK-boosting
• Analysis methods for small-molecular anticancer treatments, to support therapeutic drug monitoring

Additional duties

• PhD-advisor in the scientific board of the MUMC+ (NL: Adviseur wetenschapscommissie MUMC+)